Correspondence to Dr Licia Rivoltini, Unit of Immunotherapy of Human Tumors, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 20133, Italy; [email protected]; Dr Vincenzo Mazzaferro, HPB Surgery and Liver Transplantation Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; [email protected]; Dr Chiara Camisaschi, Unit of Immunotherapy of Human Tumors, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; [email protected]
We read with interest the recent work of Chew et al1 and we would like to share some original data that might implement the concept of immune activation as a consequence of Yttrium90 transarterial radioembolisation (Y90TARE) in hepatocellular carcinoma (HCC). In this study,1 Y90TARE was shown to mediate a significant increase in activated T and NK cells at the site of the tumour and in the peripheral blood of patients with HCC. The increase in these cell populations, particularly T cells expressing specific homing receptors (CCR5 and CXCR6), is associated with local tumour control.
In our study, we monitored immune phenotypes in the blood (figure 1A) of intermediate-advanced HCC patients (n=49) with preserved hepatic function, undergoing Y90TARE treatment during a 2-year period in our centre (table 1).
We observed that tumour irradiation causes an altered adaptive and innate immune response, including an increased frequency of activated CD3+ T cells and CD8+ subsets, regulatory T cells (Treg) and inflammatory (PD-L1+ and HLA-DR+) monocyte populations (online supplemental figure). The immunomodulatory effect peaked 1 month after treatment and decreased significantly at 3 and 6 months, indicating the short-term nature of Y90TARE-induced immunomodulation (figure 1B).作者: StephenW 时间: 2022-5-7 06:44